CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Net (loss) income before equity in losses of unconsolidated affiliates	$ (594)	$ (17,217)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:
Depreciation and amortization	10,084	8,041
Non-cash impact of operating leases	1,582	1,431
Deferred income tax (benefit) expense	(4,043)	1,268
Stock-based compensation	14,861	6,930
Change in fair value of contingent consideration	(744)	0
Equity in losses of unconsolidated affiliates	837	300
Accretion of discounts and issuance costs	48	4,573
Other losses	1,057	62
Changes in operating assets and liabilities (net of the effect of acquisitions):
Accounts receivable	5,504	(1,813)
Inventories	(9,286)	(3,901)
Other assets	(6,885)	(1,423)
Accounts payable	(2,913)	(2,708)
Other liabilities	(4,236)	(3,644)
Net cash provided by (used in) operating activities	5,272	(8,101)
Cash flows from investing activities:
Promissory note receivable issuance	(9,000)	0
Purchases of property and equipment	(993)	(486)
Proceeds from disposition of property and equipment	42	0
Net cash used in investing activities	(34,596)	(120,043)
Cash flows from financing activities:
Payment of stock issuance costs	(314)	(214)
Preferred stock proceeds	0	122,000
Proceeds from issuance of common stock	168,770	2,050
Repurchase of common stock	(1,503)	(652)
Repayments of other debt	(821)	(193)
Borrowings on other debts	0	508
Net cash provided by financing activities	166,132	123,499
Foreign exchange effect on cash and cash equivalents	(242)	123
Net increase (decrease) in cash and cash equivalents	136,566	(4,522)
Cash and cash equivalents, beginning of period	86,334	89,030
Cash and cash equivalents, end of period	222,900	84,508
Supplemental disclosure of cash flow information:
Non-cash transfers of equipment between inventory and property and equipment, net	3,678	3,328
Non-cash conversion of preferred stock to common stock	0	122,000
Contingent consideration for acquisitions	3,290	0
Notes payable	15,900	0
Purchase price adjustment receivable for scil	0	1,273
Indemnity holdback for acquisition	346	0
CVM
Cash flows from investing activities:
Acquisition of CVM	0	(14,420)
Lacuna Diagnostics, Inc.
Cash flows from investing activities:
Acquisition of CVM	(3,882)	0
Biotech
Cash flows from investing activities:
Acquisition of CVM	(16,250)	0
BiEsseA s.r.1.
Cash flows from investing activities:
Acquisition of CVM	(4,513)	0
Scil Animal Care Company
Cash flows from investing activities:
Acquisition of CVM	$ 0	$ (105,137)